Evidence map›Paper›PMID 34618370›Full record

ArticleThe EMBO journal2021

MARCO

Kathryn S Carpentier, Ryan M Sheridan, Cormac J Lucas, Bennett J Davenport, Frances S Li, Erin D Lucas, Mary K McCarthy, Glennys V Reynoso, Nicholas A May, Beth A J Tamburini and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in The EMBO journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. From defense to disease: the multifaceted role of lymphatics during infection.Journal of immunology (Baltimore, Md. : 1950) · 2025
    Review
  7. Article
  8. AXL promotes lymphangiogenesis by amplifying VEGF-C-mediated AKT pathway.Cellular and molecular life sciences : CMLS · 2025
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Ly6CCell reports · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Kathryn S CarpentierDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Ryan M SheridanRNA Bioscience Initiative, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0003-4012-3147
Cormac J LucasDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Bennett J DavenportDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Frances S LiDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0001-8798-8290
Erin D LucasDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Mary K McCarthyDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Glennys V ReynosoViral Immunity and Pathogenesis Unit, Laboratory of Clinical Microbiology and Immunology, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Nicholas A MayDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Beth A J TamburiniDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Jay R HesselberthRNA Bioscience Initiative, University of Colorado School of Medicine, Aurora, CO, USA.
Heather D HickmanViral Immunity and Pathogenesis Unit, Laboratory of Clinical Microbiology and Immunology, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Thomas E MorrisonDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0002-1811-2938
University of Colorado Denver · USNational Institute of Allergy and Infectious Diseases · USUniversity of Colorado Anschutz Medical Campus · US

Funding

TRAINING PROGRAM IN IMMUNOLOGYT32AI007405 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Laurel L Lenz, Raul Martin Torres · 1991 to 2026
$10.5M
Nanopore analysis of transfer RNA forms and functionsR35GM119550 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI Jay R Hesselberth · 2016 to 2026
$4.5M
Cooperation between lymphatic stroma and hematopoietic cells shapes protective immunityR01AI121209 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Beth Ann Tamburini · 2016 to 2026
$4.5M
Molecular Mechanisms of Immune ToleranceT32AI074491 · NIAID · NATIONAL JEWISH HEALTH · PI CAMBIER, JOHN C, PELANDA, ROBERTA · 2009 to 2023
$4.1M
Predoctoral Training Program in Molecular and Cellular Biology (Supplement: Mentoring in the Research Environment)T32GM136444 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI MICHAEL A MCMURRAY, Rytis Prekeris · 2020 to 2026
$3.7M
Biochemistry at single-cell resolution: a new approach to understand functional heterogeneityR01AG071467 · NIA · UNIVERSITY OF COLORADO DENVER · PI HESSELBERTH, JAY R · 2020 to 2024
$3.2M
Impairment of B cell Responses by Pathogenic Chikungunya VirusesR01AI141436 · NIAID · UNIVERSITY OF COLORADO DENVER · PI DIAMOND, MICHAEL S, MORRISON, THOMAS E · 2019 to 2023
$3.2M
Molecular Pathogenesis of Infectious DiseasesT32AI052066 · NIAID · UNIVERSITY OF COLORADO DENVER · PI VAN DYK, LINDA F. · 2002 to 2022
$2.3M
Clearance of Blood-Borne ArbovirusesR01AI148144 · NIAID · UNIVERSITY OF COLORADO DENVER · PI MORRISON, THOMAS E · 2020 to 2025
$2.3M
PD-L1 reverse signaling in dermal DCs promotes DC migration and skin immunity to cutaneous pathogensR01AI155474 · NIAID · UNIVERSITY OF COLORADO DENVER · PI TAMBURINI, BETH ANN · 2020 to 2024
$2.3M
Mechanisms of adaptive immune suppression during pathogenic chikungunya virus infectionF32AI122463 · NIAID · UNIVERSITY OF COLORADO DENVER · PI MCCARTHY, MARY KATHERINE · 2016 to 2018
$174k
Viral and Host Determinants of Chikungunya Virus DisseminationF32AI140567 · NIAID · UNIVERSITY OF COLORADO DENVER · PI CARPENTIER, KATHRYN SEMMENS · 2018 to 2021
$170k
NIAID NIH HHS F32 AI122463NIAID NIH HHS F32 AI140567NIAID NIH HHS R01 AI121209NIAID NIH HHS R01 AI141436NIAID NIH HHS R01 AI148144NIAID NIH HHS R01 AI155474NIAID NIH HHS T32 AI007405NIAID NIH HHS T32 AI052066NIAID NIH HHS T32 AI074491NIA NIH HHS R01 AG071467NIGMS NIH HHS R35 GM119550NIGMS NIH HHS T32 GM136444
6 · The paper itself

Abstract

Viremia in the vertebrate host is a major determinant of arboviral reservoir competency, transmission efficiency, and disease severity. However, immune mechanisms that control arboviral viremia are poorly defined. Here, we identify critical roles for the scavenger receptor MARCO in controlling viremia during arthritogenic alphavirus infections in mice. Following subcutaneous inoculation, arthritogenic alphavirus particles drain via the lymph and are rapidly captured by MARCO+ lymphatic endothelial cells (LECs) in the draining lymph node (dLN), limiting viral spread to the bloodstream. Upon reaching the bloodstream, alphavirus particles are cleared from the circulation by MARCO-expressing Kupffer cells in the liver, limiting viremia and further viral dissemination. MARCO-mediated accumulation of alphavirus particles in the draining lymph node and liver is an important host defense mechanism as viremia and viral tissue burdens are elevated in MARCO

Indexed as

AlphavirusAlphavirus InfectionsAnimalsChikungunya FeverEndothelial CellsHost-Pathogen InteractionsKupffer CellsLymph NodesMiceMice, Inbred C57BLMice, Mutant StrainsMice, TransgenicReceptors, ImmunologicRNA, ViralSingle-Cell AnalysisViremiaMarco protein, mouseReceptors, ImmunologicRNA, ViralarbovirusKupffer cellslymphatic endothelial cellsMARCOviremia

Identifiers

PMID34618370
PMCPMC8591538
OpenAlexW3204196523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.